Combining retifanlimab (Zynyz) with standard-of-care chemotherapy significantly improved progression-free survival (PFS) in treatment-naïve patients with locally advanced or metastatic squamous cell ...

New KEYNOTE-B96 data add to previous results showing progression-free survival (PFS) and overall survival (OS) improvements vs placebo. In our study, we first of all included 643 patients. We ...

HONG KONG, Oct. 30, 2025 /PRNewswire/ -- Akeso (9926.HK) is excited to announce that the significant results from the final overall survival analysis of the Phase III HARMONi-A study, which evaluates ...

Zepzelca plus Tecentriq improved PFS and OS in ES-SCLC patients compared to Tecentriq alone, with a median PFS of 5.4 months versus 2.1 months. The combination therapy showed a median OS of 13.2 ...

MRD negativity in MM patients correlates with improved survival, suggesting its potential as a surrogate marker for survival outcomes. Novel therapeutics complicate the assessment of PFS and OS, ...

DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom ...

SAN FRANCISCO -- Progression-free survival (PFS) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) more than doubled with the addition of the somatostatin analog (SSA) lanreotide (Somatuline ...

The ability of the Geneva homologous recombination deficiency (HRD) test to predict progression-free survival (PFS) in patients with high-grade ovarian cancer treated with poly (ADP-ribose) polymerase ...